Targets › PDCD1LG2
17 programs from 17 companies in 37 trials: 20 Phase 1, 15 Phase 2, 2 Phase 3; Oncology; next expected readout Nov 2026.
Plays a critical role in induction and maintenance of immune tolerance to self. Acts as a ligand for the inhibitory receptor PDCD1/PD-1, inhibiting T-cell proliferation by blocking cell cycle progression and cytokine production. (UniProt, Q9BQ51)
Open in Phaseline: the race on PDCD1LG2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Biotheus | PM8002 bispecific antibody targeting PD-L1 and VEGF | CD274, VEGFA, PDCD1LG2 | Phase 3 | SCLC; Triple Negative Breast Cancer(TNBC); NSCLC; Neuroendocrine Neoplasm … | Jan 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Adbelimumab PD-1/PD-L1 pathway inhibitor; anti-PD-L1 monoclonal antibody | PDCD1LG2 | Phase 2 | Esophageal Squamous Cell Carcinoma | Dec 2026 |
| National Cancer Institute (NCI) | PDS01ADC Anti-PD-L2 antibody-drug conjugate | PDCD1LG2 | Phase 2 | Cancer Of Prostate; Metastatic Colorectal Cancer (Mcrc); Prostate Cancer; Kaposi Sarcoma … | Dec 2026 |
| The First Affiliated Hospital of Zhengzhou University | SHR1701 PD-L1 and TGFβ dual inhibitor | PDCD1LG2, TGFB1 | Phase 2 | Advanced Gastric Cancer | Jul 2027 |
| Peking University Cancer Hospital & Institute | [18F]F-PDL1-3 PD-L1-targeted radionuclide probe (18F-labeled imaging agent) | PDCD1LG2 | Phase 2 | Lung Cancer (NSCLC) | Jul 2027 |
| Hubei Cancer Hospital | Lvonescimab (AK112) PD-L2 inhibitor | PDCD1LG2 | Phase 2 | Breast Cancer | Sep 2027 |
| Fudan University | TQB2450 PD-L1 inhibitor | PDCD1LG2 | Phase 2 | Endometrial Cancer | Oct 2027 |
| Chia Tai Tianqing Pharmaceutical Group | Benmelstobart injection PD-L1 inhibitor | PDCD1LG2 | Phase 2 | Alveolar Soft Part Sarcoma | Nov 2027 |
| Obstetrics & Gynecology Hospital of Fudan University | Tuvonralimab PD-L2 inhibitor | PDCD1LG2 | Phase 2 | Cervical Cancers | Mar 2028 |
| Boehringer Ingelheim | Ezabenlimab PD-L2 inhibitor antibody | PDCD1LG2 | Phase 1 | Carcinoma, Squamous Cell of Head and Neck (HNSCC); Solid Tumors; Small Cell Lung Carcinoma (SCLC); Neoplasms … | Nov 2026 |
| FBD Biologics | HCB301 Engineered SIRPα fused to anti-PD-L1 and TGF-β fusion protein | SIRPA, PDCD1LG2, TGFB1 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| MediLink Therapeutics (Suzhou) | Ivonescimab (AK112) Bispecific antibody targeting PD-L1 and CTLA-4 | PDCD1LG1, PDCD1LG2 | Phase 1 | Advanced Solid Tumors | Jan 2027 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | [18F]DK222 PD-L1-targeted radiotracer for PET-CT imaging | PDCD1LG2 | Phase 1 | Non-Small Cell Lung Cancer | Jan 2028 |
| Jun Zhou | IUAb190708 cytotoxic anti-PD-L1 antibody | PDCD1LG2 | Phase 1 | Solid Tumor Cancer | Jun 2028 |
| University of California, Irvine | COH06 Genetically engineered NK cells expressing PD-L1 and expressing/secreting IL-15 | PDCD1LG2, IL15 | Phase 1 | Advanced Lung Non-Small Cell Carcinoma | Nov 2028 |
| Pfizer | PF-08046054/SGN-PDL1V PD-L1-targeted antibody-drug conjugate | PDCD1LG2 | Phase 1 | Advanced/Metastatic Non-Small Cell Lung Cancer | Mar 2029 |
| GSK | Ivonescimab PD-L2 inhibitor | PDCD1LG2 | Phase 1 | Neoplasms, Lung | Jun 2029 |
SCLC (3) Cancer Of Prostate (2) Solid Tumors (2) Triple Negative Breast Cancer(TNBC) (1) NSCLC (1) Neuroendocrine Neoplasm (1) CRC (Colorectal Cancer) (1) Malignant Neoplasm (1) TNBC (1) Breast Cancer (1) Metastatic Colorectal Cancer (Mcrc) (1) Prostate Cancer (1)
small molecule (8), antibody (5), mixed (4)
Biotheus (1) Hubei Cancer Hospital (1) National Cancer Institute (NCI) (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) FBD Biologics (1) Obstetrics & Gynecology Hospital of Fudan University (1) Boehringer Ingelheim (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) University of California, Irvine (1) GSK (1) Fudan University (1) Jun Zhou (1) The First Affiliated Hospital of Zhengzhou University (1) Chia Tai Tianqing Pharmaceutical Group (1) MediLink Therapeutics (Suzhou) (1) Pfizer (1) Peking University Cancer Hospital & Institute (1)
TGFB1 (2) CD274 (1) VEGFA (1) SIRPA (1) IL15 (1) PDCD1LG1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.